{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkIynlpMLDA","founded_year":1999,"lastupdate":"2024-09-23T00:00:00.000Z","update_date":"2024-09-23T00:00:00.000Z","lastModified":"Oct 8, 2024","confidence_score":67,"active":1,"confidence_score_reason":"product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed","urlname":"astrazeneca","minimal_profile":null,"status":"Public","fullstatus":"Public on LSE on Jun, 1993;Public on NYSE on Jun, 1993;","acquired":0,"description_edited":0,"tag_line_edited":0,"phone":"+972732226099","registrar":"","biverification":"Maor Perlov","recentupdates":[{"email":"yayhosh@gmail.com","source":"Automatic","datetime":"2023-03-28 08:03:20.000000","last_name":"Levi Shinebox","first_name":"Ayelet"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:26:11.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-09-23 13:00:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-09-23 12:56:26.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:07:25.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-14 09:25:25.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-09-23 12:57:34.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:07:25.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-09-23 13:00:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yayhosh@gmail.com","source":"Manual","datetime":"2023-03-28 08:03:20.000000","last_name":"Levi Shinebox","first_name":"Ayelet"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-10-08 08:20:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yanina.wainscheinker@sncentral.org","source":"Manual","datetime":"2023-03-23 13:20:20.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:40:57.000000","last_name":"Levin","first_name":"Eran"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:40:56.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:05:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:07:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:07:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:07:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:07:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:07:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:07:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:07:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:09:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:09:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:12:06.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:12:06.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:33:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:37:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:45:29.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:37:46.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:12:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:12:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:28:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:51:59.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:51:59.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:09:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:06:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:06:28.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:10:02.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:05:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:50:36.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:33:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:04:40.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:04:40.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:08:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:37:36.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:13:16.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-04 06:13:16.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:27:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:00:00.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:10:02.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:11:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:11:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:11:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:11:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:11:21.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:05:30.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2022-04-07 13:05:31.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-14 09:25:25.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yayhosh@gmail.com","source":"Automatic","datetime":"2023-03-28 08:03:20.000000","last_name":"Levi Shinebox","first_name":"Ayelet"},{"email":"yanina.wainscheinker@sncentral.org","source":"Manual","datetime":"2023-03-23 13:20:20.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-14 09:25:25.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yayhosh@gmail.com","source":"Manual","datetime":"2023-03-28 08:03:20.000000","last_name":"Levi Shinebox","first_name":"Ayelet"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 15:11:32.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-09-23 12:56:26.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-09-23 12:56:26.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:52:54.000000","last_name":"Levin","first_name":"Eran"},{"email":"yayhosh@gmail.com","source":"Automatic","datetime":"2023-03-28 08:03:21.000000","last_name":"Levi Shinebox","first_name":"Ayelet"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:49:19.000000","last_name":"Levin","first_name":"Eran"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPu-g88JDA","fullname":"Maor Perlov"},"biverifydate":"2022-04-07T00:00:00.000Z","crunchbaseid":"","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Maor Perlov","creator_email":"maorperlov@gmail.com","createdate":"2022-04-04T00:00:00.000Z","lastupdatedate":"2024-09-23","hide_reason":null,"hide_reason_data":null,"logokey":"$1UntiTsF59g0hrtOZakKHLk6icPTDUucDfxzMyeSIvU2kUUwydC1yN","name":"AstraZeneca","israeliacquisitions":0,"forbesranking":161,"investmentarm":null,"investmentarmname":null,"hubname":"BeyondBio SCALE","acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":[],"alternativenames":[""],"country":"United Kingdom","inisraelsince":"2008","inisraelsincemonth":"","isisraeli":0,"marketcapital":255482782574,"marketcapitaldate":"2025-11-01T14:07:19.000Z","oneliner":"Pharmaceuticals","website":"https://www.astrazeneca.com/","employees":"51-200","employees_exact":193,"employees_overall":"50,000+","employees_overall_exact":75302,"sociallinks":{"twitter":"https://twitter.com/astrazeneca","youtube":"","facebook":"https://www.facebook.com/AstraZeneca","linkedin":"https://www.linkedin.com/company/1603","instagram":""},"social":["https://www.facebook.com/AstraZeneca","https://www.linkedin.com/company/1603","https://twitter.com/astrazeneca"],"flattenedsociallinks":"https://www.facebook.com/AstraZeneca|https://www.linkedin.com/company/1603|https://twitter.com/astrazeneca","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. \n \nAstraZeneca Israel was established at the end of 2008 and is based in Kfar Saba, employing over 100 people, specializing in sales, marketing, medical & regulatory affairs.  In addition, AstraZeneca Israel has a strong presence of scientific research and development with partnerships across the country. \n \nIn May 2019 AstraZeneca signed a MOU (memorandum of understanding) with the Israeli innovation authority, committing to invest and support the Israeli healthcare ecosystem. AstraZeneca Israel is proud to be an active part of the AstraZeneca Health Innovation Hubs network alongside the US, China, Sweden, and France \n","founded":"1999","team":[{"name":"Ohad  Goldberg","email":"ohad.goldberg@astrazeneca.com","phone":"","gender":"Male","userid":"NHIvbRwjYuHfQD3xn4EGST4YZuDjKwjDXAhoEXy68rbu0V3O3SZ4vo","bounced":false,"claimed":null,"founder":0,"urlname":"ohad-goldberg","visible":1,"memberid":"3eAT6vRRq7WbtGRagAvK0D0B5vLpVgxU3anrVWianzp5nsxkNyBOme","position":"President","last_name":"Goldberg","claimtoken":"LK3H6T9y4fuK5trEPPX8qzThRz5alRD8iDA50v3aj1yYib8GbLCymm","first_name":"Ohad ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ohad-goldberg/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-03-23 13:20:27.000000","initials":"OG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Liron  Abaranok Noy","email":"","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkMz_u4YLDA","bounced":false,"claimed":0,"founder":0,"urlname":"liron-abaranok-noy","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQzPGtnQoM","position":"Innovation & Business Excellence Director","last_name":" Abaranok Noy","claimtoken":"38d7e3c1ab49d8b0f23c43d1874f175e49cea34ea150c6adb4d31ded1efe4a94","first_name":"Liron","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/liron-abaranok-noy/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"L ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Shaon Ein-Gal","email":"sharon.eingal@astrazeneca.com","phone":"","gender":"Female","userid":"Gqw3dnDhzRpjs5TAlA3Wb2ONKRe83apEIjbB9SMgCR3NXH9YZxv98f","bounced":false,"claimed":null,"founder":0,"urlname":"gqw3dndhzrpjs5tala3wb2onkre83apeijbb9smgcr3nxh9yzxv98f","visible":1,"memberid":"zWHwfvycqufDKPgZ66cQJZZ7vjhXuelEeIsreemXJnAxAJ6eOCRptL","position":"External AI Innovation Lead","last_name":"Ein-Gal","claimtoken":null,"first_name":"Shaon","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"SE","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[{"name":"DenovAI Biotech","hidden":false,"raised":"$4M","founded":"2023","fullurl":"/company_page/denovai-biotech","logokey":"$sKv2HHCkOf6ofNHG7xzLi6r5pvPdbPDxYVSzqT95KlInoFaTZh7fTI.jpeg","urlname":"denovai-biotech","employees":"11-50","company_id":"2VZkgKeesZ0du1qr3C2nYLB9r2rgw8v4tquEkKQbCRm0cSESuzTA1t","description":"Dynamic Protein Design","fundingstage":"Seed","businessmodel":"B2B","raisedNumber":4000000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$sKv2HHCkOf6ofNHG7xzLi6r5pvPdbPDxYVSzqT95KlInoFaTZh7fTI.jpeg","style":"","hiddenCompanyTooltip":""},{"name":"ProPhet","hidden":false,"raised":"$1M","founded":"2024","fullurl":"/company_page/prophet","logokey":"$8ue4OYBKbKPMzVYlnM8vodJ4LFhV99NeAK4Rea0Mgtuo4UvrQx6bWf.jpeg","urlname":"prophet","employees":"1-10","company_id":"8VzV5dnlMSswDnHZmbOuzK6cMlAuJor2dnxIvrSnT5y9v0gvJQp9ka","description":"AI-driven Drug Discovery","fundingstage":"Pre-Seed","businessmodel":"B2B","raisedNumber":1000000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$8ue4OYBKbKPMzVYlnM8vodJ4LFhV99NeAK4Rea0Mgtuo4UvrQx6bWf.jpeg","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[],"affiliatedOrganizations":[{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KarzuIKDA","name":"BeyondBio SCALE","type":"Corporate Accelerator","hidden":false,"fullurl":"/program_page/beyondbio-scale","logokey":"$GKQys2ISctzGq4yatr4EcHcNR7XHE0b24C47VOPM2pB8FpW4zM9QbS","logourl":"https://storage.googleapis.com/clean-finder-353810/$GKQys2ISctzGq4yatr4EcHcNR7XHE0b24C47VOPM2pB8FpW4zM9QbS","onClick":"","visibilityClassName":"","visibilityTooltip":""}],"address":{"israeli":[{"id":"6d6731be-0f8b-4d8c-a989-eecf1acfb840","city":"Kefar Sava","type":["Sales","Innovation center"],"address":"Atir Yeda Street 1, Kefar Sava, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":"51402055","firstrdcenter":0,"registrarname":"AstraZeneca (Israel) Ltd"}],"officesabroad":[{"id":"vC31MsAG6mQ5HOHtOfFo8v2XWu7gtAeKd6YVVYSv3PVY9RrznKIk62","city":"Cambridge","address":"Cambridge, UK","country":"United Kingdom","placeid":"ChIJLQEq84ld2EcRIT1eo-Ego2M"}]},"headquarter_address":"Cambridge, UK","news":[{"id":"WAKMcaWRwcqJSODMwpS5lW9Nm96Rs8wuFiZ3UCafuSGRk12QIN2uWH","date":"Oct 20, 2025","link":"https://finance.yahoo.com/news/3-uk-stocks-may-undervalued-063754019.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["undervalued","growth"],"round":null,"company":"Nichols plc","layoffs":null,"summary":"Nichols plc, a company with a market cap of £396.78 million, supplies soft drinks to various industries globally. The company is trading at a 41.9% discount to its estimated fair value, suggesting it is significantly undervalued. Despite a slight dip in recent earnings, Nichols forecasts robust annual profit growth of 16.4%, surpassing the UK market average. Analysts predict a potential stock price increase of 34.8%. However, the company has an unstable dividend track record, and recent executive changes could affect future performance stability. Overall, Nichols is poised for substantial financial growth, making it an attractive option for investors seeking undervalued stocks.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["undervalued stocks","market analysis","profit growth","dividend stability","executive changes"],"date_of_event":"October 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cBm4Pu0Bb9lE7fkIRvIzkn7jwSgeMkSUwfOLR4sbT7f8FhXdgklqfU","news_summary":"3 UK Stocks That May Be Undervalued In October 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"kwhOeJgFDd06w35gniBk3K4jnhsECgYaef5ecoZytHTo1Qj0Dnq65j","date":"Oct 8, 2025","link":"https://finance.yahoo.com/news/astrazenecas-baxdrostat-meets-goal-resistant-151500159.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"AstraZeneca","layoffs":null,"summary":"AstraZeneca announced positive results from the phase III Bax24 study, which evaluated the safety and efficacy of baxdrostat in patients with resistant hypertension. The study showed that baxdrostat significantly reduced systolic blood pressure compared to placebo, with efficacy observed over a 24-hour period. The treatment was well tolerated, with a safety profile similar to previous studies. AstraZeneca plans to share these results with global regulatory authorities. The company has seen a 31.1% increase in shares year-to-date, outperforming the industry average. Baxdrostat is also being investigated for other conditions, including primary aldosteronism and chronic kidney disease.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["hypertension","baxdrostat","clinical trial","blood pressure","aldosterone"],"date_of_event":"2023","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XlhFQAGiafQL7Zo8x99GtalrQKbyHkIY4CjS3iuAt6bSs0UGjyS4r8","news_summary":"AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cRzp5ReN5mRaYKYBeCPnoOzJ9o1KRYnYp7FSgzxGCSki1h3iOkEkWz","date":"Jul 3, 2025","link":"https://finance.yahoo.com/news/sector-health-care-stocks-mixed-172001656.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":null,"round":null,"company":null,"layoffs":null,"summary":"The article provides a brief update on the performance of healthcare stocks on a Thursday afternoon, noting that the NYSE Health Care Index was down by 0.1%. However, the article is behind a paywall, and further details are not accessible without a subscription to MT Newswires. The article mentions several stock symbols, including AZN.L, SMMT, XLV, TH.TO, and CMND, but does not provide specific information about any particular company or event. As such, no detailed analysis or classification of impact, issues, or other specifics can be determined from the available text.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":8,"key_topics":[],"date_of_event":"July 3, 2025","product_stage":null,"investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":null,"investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"5lTxxxUypD1gmIXZzlR2B2PGFRFzDcPMBLqMiS0duZ3M1geq2Id99M","news_summary":"Sector Update: Health Care Stocks Mixed Thursday Afternoon","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"PqDgC5LaPKKKHR3m2okJtfD7pXTqpH0KJnXji2QXGnQC5EB2rejQ4K","date":"Jul 1, 2025","link":"https://finance.yahoo.com/news/sector-health-care-stocks-rise-195638369.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":null,"round":null,"company":null,"layoffs":null,"summary":"The article is a brief mention of health care stocks advancing late Tuesday afternoon, with references to the NYSE Health Care Index. It does not provide specific details about any particular company, investment, or event. The text is part of a premium news service, suggesting that more detailed information is available to subscribers. No specific company actions, partnerships, or financial details are discussed in the provided text.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":8,"key_topics":[],"date_of_event":"July 1, 2025","product_stage":null,"investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":null,"investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"YxpfWlEee0JpewyTuTaY5wsuk88yal0LNyF8pdANhKKv1tdaLUaWIC","news_summary":"Sector Update: Health Care Stocks Rise in Late Afternoon Trading","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"U1daZtasKa9lnthLQWVnNX5rD2ceLJ7fTz83jei2KKVG7dITeRztOw","date":"Jun 24, 2025","link":"https://www.thedailyupside.com/economics/international-economics/markets-discount-anxiety-over-us-iran-military-strikes/","source":"www.thedailyupside.com","visible":1,"analysis":{"tags":"geopolitics","round":null,"company":null,"layoffs":null,"summary":"The article discusses recent geopolitical tensions between the United States and Iran, following US attacks on Iranian nuclear facilities and Irans retaliatory missile strikes on a US airbase in Qatar. Despite initial fears of escalating conflict, diplomatic efforts led to a ceasefire agreement between Israel and Iran, announced by President Donald Trump. This de-escalation reassured global markets, with oil prices dropping significantly and stock indices like the S&P 500, Nasdaq, and Dow Jones rising. The article also mentions Irans parliamentary vote to potentially close the Strait of Hormuz, a critical oil trade route, though such a move seems unlikely. Overall, the situation appears to be stabilizing, with investors responding positively to the developments.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["ceasefire","oil prices","diplomacy","markets","Iran"],"date_of_event":"2023-10-16","product_stage":null,"investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":null,"investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"bdAg3LPMdW1YpDegueQKmhS1piLb9meIp01KSFAerjh62qRZGyT7Wb","news_summary":"Markets Stay Relatively Calm as Fragile Ceasefire Deal Follows Missile Strikes","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"YOt6a5Z83BIyAGIIeu2I5EaM6jWU97VnDEikbx26TlvRoXva4tiklb","date":"Jun 13, 2025","link":"https://www.biopharmadive.com/news/astrazeneca-ai-deal-china-third-harmonic-liquidation/750601/","source":"www.biopharmadive.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"AstraZeneca","layoffs":null,"summary":"AstraZeneca has formed a new collaboration with CSPC Pharmaceutical Group to develop oral medicines using AI technology for immunological diseases and other chronic conditions. The deal involves an upfront payment of $110 million to CSPC and potential additional payments up to $5.2 billion based on development and sales milestones. This partnership builds on AstraZenecas previous investments in China, including a $2.5 billion R&D center in Beijing and collaborations with other Chinese biotechs. The collaboration is part of AstraZenecas strategy to deepen its presence in the Chinese market and leverage AI in drug discovery.","partners":"CSPC Pharmaceutical Group","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["collaboration","investment","AI technology","drug development","China market"],"date_of_event":"June 13, 2025","product_stage":"R&D","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$110 million upfront, up to $5.2 billion in milestones","structured_issues":["Partners","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cdmSKRrWbuBtotBvPy2NOMcHMfUyGkVqmAO0VV0HfJyBDUQkQV2fF5","news_summary":"AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"sVNsXp5JgykzJhklIb3b0oFMBfkedAD757gQloJRMHA1oj9HTycblO","date":"Apr 28, 2025","link":"https://en.globes.co.il/en/article-astrazeneca-sets-up-tel-vviv-center-to-study-israeli-health-data-1001509035","source":"en.globes.co.il","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"AstraZeneca","layoffs":null,"summary":"AstraZeneca has launched the Beam - Illuminating Healthcare Through Data Center in collaboration with Tel Aviv University and the Leumit and Meuhedet health funds. This initiative aims to leverage Israeli digital medical data to enhance understanding of disease mechanisms and improve patient care. The center will utilize anonymized data from health insurance companies, employing AI tools to analyze real-world data. This collaboration between academia, industry, and health services is expected to advance research and medical services, with a focus on data privacy through federated learning. The center represents a significant step forward in data science within the health sector.","partners":["Tel Aviv University","Leumit","Meuhedet"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["data analysis","AI tools","healthcare","research center","collaboration"],"date_of_event":"April 28, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":"using","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1TAdW0BbHGWP5jHCChAFwSBlPxey3PA9bxrDfNIdGlQv2faWZLDJrZ","news_summary":"The UK pharmaceutical giant is teaming with Tel Aviv University and the Meuhedet and Leumit health funds on the project.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"YtakVgx8oTsHXVEVoY4jpMM9L2eUimXmXZ56weiyh0D9apUHK2Uzeh","date":"Sep 26, 2024","link":"https://www.timesofisrael.com/israeli-ai-startup-forges-18m-partnership-with-astrazeneca-for-cancer-drug-trials/","source":"www.timesofisrael.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"549fv6jhLJzjbR1n6tTWhnJ0Tb6DTVSRTvOEH2dpDQmRbCJGllbDlt","news_summary":"Israeli AI startup forges $18m partnership with AstraZeneca for cancer drug trials","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"RWAWclkZ19STPG5f1LypBXXM7dBSR2vBLVECz2ZuKxXlMuJsOTtWPN","date":"Feb 8, 2024","link":"https://www.wsj.com/business/earnings/astrazeneca-azn-q4-earnings-report-2023-ca5eb4ad?siteid=yhoof2","source":"www.wsj.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"FF5dCPWFn2oWDcG9uaMAGkXED15pPst8clnPSIdYYneYeugxg5O2o6","news_summary":"AstraZeneca Shares Drop on Weak Quarterly Report Despite 2024 Growth Guidance","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"usTR6vajT0iRg1qZhQh0E7k0YR1RNJXrQV8qvELBBfAV5Ng0WS99WA","date":"Jan 21, 2024","link":"https://www.jpost.com/business-and-innovation/article-782679","source":"www.jpost.com","visible":1,"analysis":{"tags":"partnership","company":"Immunai","layoffs":null,"summary":"Immunai, an American-Israeli immunomics company, has announced a successful collaboration with AstraZeneca, utilizing its AI-based Clinical Trial Optimization engine to support the development of AstraZenecas drug, Volrustomig. Immunais technology provided deep immunological insights that were instrumental in advancing the drug through clinical trial phases. This partnership highlights Immunais role in enhancing drug development efficiency and effectiveness. The company leverages its extensive immune database, AMICA, and advanced AI to generate valuable data-driven insights, potentially reducing drug development time and costs. Immunai operates internationally with a team of 160 members and aims to become a market leader in the biopharmaceutical sector.","partners":["AstraZeneca"],"customers":[],"investors":[],"confidence":10,"key_topics":["AI","Clinical Trials","Immunotherapy","Pharma","FDA"],"date_of_event":"2024-01-18","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8jAw7EP02iTpVInKhIeJYh5V8MqV5fpRknt2XhDdIipUcnUmAZrHZX","news_summary":"Israel’s Immunai could be the secret weapon to faster drug approvals\nAmerican-Israeli company announces latest success story with AstraZeneca.\n","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3f98dbe6-4508-4227-8645-516cd7022eeb","date":"Apr 3, 2022","link":"https://www.calcalistech.com/ctechnews/article/byiewmv7q","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"innovation, partnerships","company":"AstraZeneca","layoffs":null,"summary":"AstraZenecas BioVentureHub, in partnership with the Swedish government, aims to combine science and tech to support the growth of small organizations. The hub, located in Gothenburg, provides access to AstraZenecas human capital and infrastructure for startups. The initiative also collaborates with The Connector, an innovation program between Sweden and Israel. AstraZeneca has signed an MOU with the Israeli Innovation Authority and has been working with The Connector to support the Israeli healthcare ecosystem. The BioVentureHub has collaborations with various companies, fostering a dare to share culture. AstraZeneca has also established HealthWorks, a hub focused on patient centricity. The company is interested in establishing relationships with Israeli companies and utilizing governmental funding to support them.","partners":"Swedish government, The Connector","customers":null,"investors":null,"confidence":9,"key_topics":["BioVentureHub","innovation","partnerships","Israeli startups","growth journey"],"date_of_event":"May 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"A2nuGpczksnZDebvxKlTWwjsNykKw3zMpJgJginfe1ehEg6REpzkla","news_summary":"AstraZeneca innovation hub seeking Israeli tech as it broadens search for innovation  CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3f1e9d6c-e390-43a4-9933-30fa9aeebcee","date":"Oct 19, 2021","link":"https://www.jpost.com/health-and-wellness/pfizer-astrazeneca-help-launch-computational-science-lab-in-israel-682248","source":"www.jpost.com","visible":1,"analysis":{"tags":"computational science, drug discovery, AI technologies","company":"Aion Labs","layoffs":null,"summary":"Aion Labs, a computational science lab focused on drug discovery, has launched its headquarters in Israel. The lab is a partnership between AstraZeneca, Merck, Pfizer, Teva, Amazon Web Services, and Israel Biotech Fund. Aion aims to create and adopt new AI technologies to transform the drug discovery and development process. The lab will have a wet lab for biomedical experiments and a cloud-based computational lab environment for developing new algorithms. The partners hope to improve predictability, reduce time, and save money in drug development, as well as position Israel as a leader in the pharma R&D industry. AION Lab also plans to support the growth of start-ups in the biotech space. AION has signed with BioMed X and is working with Start-up Nation Central and Science Abroad to attract Israeli life science experts.","partners":["AstraZeneca","Merck","Pfizer","Teva","Amazon Web Services","Israel Biotech Fund","BioMed X","Start-up Nation Central","Science Abroad"],"customers":null,"investors":null,"confidence":8,"key_topics":["Computational science","Drug discovery","AI technologies","Partnership","Start-ups"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"i2t1xP8m5MYXqWvBSXQEjQYT3ZcM6JFwACJl7LFwZgC6xF86pRjxIc","news_summary":"https://www.jpost.com/health-and-wellness/pfizer-astrazeneca-help-launch-computational-science-lab-in-israel-682248","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LOAsb3bdYzaPj3Zt9DCfQHVdgABkmmgGoVdU0sqVaQDJeHlTCqMUHo","date":"Feb 24, 2020","link":"https://www.jvpvc.com/press-releases/jvp-astrazeneca-launch-joint-digital-health-initiative/","source":"www.jvpvc.com","visible":1,"analysis":{"tags":"digital health","company":"PlayBeyondBio","layoffs":null,"summary":"Internationally renowned VC JVP and AstraZeneca have launched the call for application for PlayBeyondBio, a program designed to attract, screen, develop, and promote innovative startups in the digital health field. PlayBeyondBio is a strategic partnership between AstraZeneca, JVP, and Israel Initiative, in collaboration with other organizations. The program aims to supercharge digital health startups by providing guidance, mentorship, and access to resources. The selected startups will receive exclusive guidance from AstraZeneca and JVP experts, as well as support from Microsoft for Startups. PlayBeyondBio will focus on various clinical areas and technological solutions. Applications close on March 11th, 2020.","partners":["AstraZeneca","JVP","Microsoft for Startups"],"customers":null,"investors":null,"confidence":9,"key_topics":["PlayBeyondBio","digital health","startups","AstraZeneca","JVP"],"date_of_event":"2020-02-24","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uqzxLJ3JdHqj5ULWrGrN2RLJhSeVm090wm5mg4jdmST1I8vSjASWyk","news_summary":"JVP and AstraZeneca Launch Joint Digital-Health Initiative - JVP","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":[{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KarzuIKDA","name":"BeyondBio SCALE","type":"Corporate Accelerator","hidden":false,"logokey":"$GKQys2ISctzGq4yatr4EcHcNR7XHE0b24C47VOPM2pB8FpW4zM9QbS","subtype":null,"urlname":"beyondbio-scale","isisraeli":0,"entitytype":"Corporate Accelerator","fullUrlname":"/program_page/beyondbio-scale","fundingstages":null}],"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCs9MGtCAw","hub":null,"date":"1993-06-01","batch":"","token":"","amount":null,"hub_id":null,"source":"","ticker":"(FORMER AZE) AZN","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"LSE","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCozKWUCQw","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$E83RXxMVGwp7cm0L2Z0i2ni1EON0UyaH6ehVTD4KOSAdnkUnZNQ7wV","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$E83RXxMVGwp7cm0L2Z0i2ni1EON0UyaH6ehVTD4KOSAdnkUnZNQ7wV","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDMqvvqCQw","hub":null,"date":"1993-06-01","batch":"","token":"","amount":null,"hub_id":null,"source":"","ticker":"AZN","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""}],"techcommunityinvolvement":null,"tags":["innovation-center","pharmaceuticals","oncology","biopharmaceutical","immunology","clinical-trials"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"50,000+","fundingtype":"Multinational","parsedName":"AstraZeneca","logourl":"https://storage.googleapis.com/clean-finder-353810/$1UntiTsF59g0hrtOZakKHLk6icPTDUucDfxzMyeSIvU2kUUwydC1yN","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$1UntiTsF59g0hrtOZakKHLk6icPTDUucDfxzMyeSIvU2kUUwydC1yN","teamMembersNumber":3,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}